Medigene eyeing more immunotherapy deals after Bluebird pact

FRANKFURT (Reuters) - German biotech firm Medigene said it is drawing more interest from prospective alliance partners for its technology to boost the immune response to cancer after its deal with U.S. peer Bluebird Bio.